Diffuse Large Cell Lymphoma


Related Videos (117)

In this, the second of three videos in which Sunita Nasta, MD, FACP reviews findings from ASH on the aggressive lymphomas, Dr. Nasta considers diffuse large B cell lymphomas (DLBCL). Among other advances, her presentation includes an overview of current investigational targeted therapies and a consideration of RCHOP therapies, as well as the introduction of two agents, a novel, oral dual inhibitor of histone deacetylas and P13K and venetoclax monotherapy, for patients with relapsed/refractory DLBCL.

To view other parts of this program:

Part 1: Mantle Cell Lymphoma

Part 3: T-Cell Lymphoma


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®